<?xml version="1.0" encoding="UTF-8"?>
<ref id="B99-antioxidants-09-00962">
 <label>99.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Harris</surname>
    <given-names>C.L.</given-names>
   </name>
   <name>
    <surname>Pouw</surname>
    <given-names>R.B.</given-names>
   </name>
   <name>
    <surname>Kavanagh</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Sun</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Ricklin</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Developments in anti-complement therapy; from disease to clinical trial</article-title>
  <source>Mol. Immunol.</source>
  <year>2018</year>
  <volume>102</volume>
  <fpage>89</fpage>
  <lpage>119</lpage>
  <pub-id pub-id-type="doi">10.1016/j.molimm.2018.06.008</pub-id>
  <pub-id pub-id-type="pmid">30121124</pub-id>
 </element-citation>
</ref>
